This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FMO1 · Western blot design guide
FMO1 Western Blot Planning Guide
Plan a FMO1 Western blot around the catalog-observed 60.3 kDa band, image-backed PB9589 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
FMO1 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 60.3 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Kidney | |
| Negative control | Appendix |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 60.3 kDa |
| ⓘ | Localization | Endoplasmic reticulum membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Sample controls for FMO1 Western blot
🧪Use Kidney as the first positive-control candidate and Appendix as the HPA Not detected negative candidate.
Positive control: Kidney (Medium)
Negative control: Appendix (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for FMO1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart on each tissue page — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Kidney | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Caudate | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Cerebral cortex | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Hippocampus | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 1
What Is the Expected FMO1 Western Blot Band Size?
Use the product-observed 60.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 60.3 kDa | Matches the authoritative product WB observation. |
| 60.3 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected FMO1 appearancePlan around 60.3 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 60.3 kDa; use this as the primary experimental expectation. |
| Calculated mass | 60.3 kDa from UniProt Q01740; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9589. |
| Situation | Likely cause | Next action |
|---|---|---|
| 60.3 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing FMO1 band
PB9589 · FMO1Observed 60.3 kDa · product-specific WB image
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Section 2
Real Curated FMO1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Caudate |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9589 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 4
Advanced FMO1 Western Blot Tips
Deeper troubleshooting and optimisation questions for FMO1, answered from its protein features.
Which band should guide the blot?
Use 60.3 kDa, the observation attached to the authoritative PB9589 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 60.3 kDa expectation.
Which positive control should I start with?
Start with Kidney, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Appendix as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for FMO1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9589 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC10558214, PMC3771112, PMC11046708.
Boster reagents
FMO1 Western Blot Reagents
Human/Mouse/Rat-reactive FMO1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-FMO1 Antibody Picoband®
Cat # PB9589
Reactivity: Human, Mouse, Rat
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q01740
- Human Protein Atlas — FMO1
- PB9589 product record
- PMC10558214 — Flavin containing monooxygenase 2 regulates renal tubular cell fibrosis and paracrine secretion via SMURF2 in AKI‑CKD transformation.
- PMC3771112 — Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation.
- PMC11046708 — Spontaneously hypertensive rats exhibit increased liver flavin monooxygenase expression and elevated plasma TMAO levels compared to normotensive and Ang II-dependent hypertensive rats.